Related Experiment Video
Updated: Apr 22, 2026

Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment
Published on: June 21, 2022
[Denosumab normalized plasma calcium concentration in malignancy-associated hypercalcaemia]
Louise Størling1, Gerda Elisabeth Villadsen, Klaus Krogh
1Klinisk Farmakologisk Afdeling, Bispebjerg -Hospital, Bispebjerg Bakke 23, 2400 København NV.
Abstract:
This case report shows how denosumab apparently treated bisphosphonate-refractory hypercalcaemia caused by a neuroendocrine tumour of the pancreas in a 48-year-old woman. We cannot eliminate the possibility that the patient's DOTATOC-treatment contributed to the decline in plasma calcium concentration. Preliminary results from a recent large, clinical trial, suggest that denosumab is a more potent treatment of malignancy-associated hypercalcaemia than bisphosphonates.
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
Treatment Resistant Cancers
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

